U.S. markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
8.69-0.51 (-5.54%)
Al cierre: 05:36PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 935 712 200
https://www.grifols.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo23,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Thomas H. GlanzmannExecutive Chairman1.9MN/D1958
Mr. Jose Ignacio Abia BuenacheCEO & DirectorN/DN/D1968
Mr. Alfredo Arroyo GuerraCFO & VPN/DN/D1958
Mr. Lluis Pons GomezSenior Vice President of Strategy & COO OfficeN/DN/D1983
Ms. Nuria Pascual LapeñaVP of Corporate Treasury, Risk Management Investor Relation & Sustainability OfficerN/DN/D1964
Mr. David Ian BellChief Corporate Development, Legal & Data Protection OfficerN/DN/D1954
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/DN/D1965
Mr. Camille AlpiChief Human Resources & Talent OfficerN/DN/D1981
Mr. Vicente Blanquer TorreChief Quality OfficerN/DN/D1961
Mr. Sergio Roura AdellPresident of Commercial Tech SupportN/DN/D1968
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Gestión corporativa

La calificación ISS Governance QuickScore de Grifols, S.A. a partir del 1 de junio de 2024 es 3. Las puntuaciones principales son Auditoría: 2; Junta: 4; Derechos del accionista: 8; Compensación: 5.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.